Floatz logo

Nelitolimod

Intrahepatic Cholangiocarcinoma

TriSalus Life Sciences, Inc.nucleic_acidPhase 1/2Active
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
89/ 100

Competitive context

38 Active assets in the Intrahepatic Cholangiocarcinoma cohort.

Asset / SponsorPhaseRating
Nivolumab
Virogin Biotech Canada Ltd
Phase 2BB
Durvalumab
West China Hospital
Phase 2BB
CIS-DIAMMINEDICHLOROPLATINUM II
Shanghai 6th People's Hospital
Phase 2BB
Atezolizumab
National Cancer Institute (NCI)
Phase 2B
Irinotecan
Tianjin Medical University Cancer Institute and Hospital
Phase 3B

View all 50 →

Same molecule, other indications

Nelitolimod is also rated in:

follicular lymphomaDormant
B
Indicative ·
58 / 100
View asset →
chronic lymphocytic leukemia/small lymphocytic lymphomaDormant
CCC
Indicative ·
54 / 100
View asset →
marginal zone lymphomaDormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →